Volume 6.14 | Apr 24

Prostate Cell News 6.14 April 24, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
Androgen Signaling Is a Confounding Factor for β-Catenin-Mediated Prostate Tumorigenesis
Researchers developed Ctnnb1L(ex3)/+/R26hARL/+:PB-Cre4 mice, in which transgenic androgen receptor and stabilized β-catenin are co-expressed in prostatic epithelial cells. Implantation of the prostatic epithelial cells isolated from the transgenic mice regenerated prostate intraepithelial neoplasias and prostatic adenocarcinoma lesions. [Oncogene] Abstract
Free Sample: TeSR™2 Defined, Feeder-Free and Xeno-Free Human ES and iPS Cell Medium
PUBLICATIONS (Ranked by impact factor of the journal)

Noncoding RNAs that Associate with YB-1 Alter Proliferation in Prostate Cancer Cells
Researchers identified a novel, abundant, 3′-modified short RNA antisense to Dicer1 (Shad1) that colocalized with YB-1 to P-bodies and stress granules. The expression of Shad1 was shown to correlate with that of YB-1 and whose inhibition leads to an increase in cell proliferation. [RNA] Abstract

Expression of Spermidine/Spermine N1-Acetyl Transferase (SSAT) in Human Prostate Tissues Is Related to Prostate Cancer Progression and Metastasis
Investigators showed that in cultured human prostate cancer (PCa) cells, an activation of spermidine/spermine N1-acetyl transferase enzyme initiated a polyamine oxidation pathway and generated copious amounts of reactive oxygen species in polyamine-rich PCa cells. [Prostate] Abstract

Human and Murine Prostate Basal/Stem Cells Are Not Direct Targets of Prolactin
Scientists evaluated whether prolactin (PRL) can act directly on these cells, by growing them as prostaspheres. For this, primary 3D prostasphere cultures were prepared from unfractionated cells isolated from freshly harvested human and mouse benign prostate tissues and subjected to PRL stimulation in vitro. [Gen Comp Endocrinol] Abstract

Silibinin Combination with Arsenic Strongly Inhibits Survival and Invasiveness of Human Prostate Carcinoma Cells
Investigators observed that silibinin modulated the oxidative status of human prostate carcinoma DU145 cells exposed to arsenic and inhibited cell growth and survival by primarily inducing autophagy and apoptosis. [Nutr Cancer] Abstract

Vitamin D3 Potentiates the Growth Inhibitory Effects of Metformin in DU145 Human Prostate Cancer Cells Mediated by AMPK/mTOR Signaling Pathway
Metformin and vitamin D3 all exhibit a strong antiproliferative action in numerous cancer cell lines including the human prostate cancer cells. Scientists showed that the combination of the two drugs had a much stronger effect on the DU145 human prostate cancer cells growth than either drug. [Clin Exp Pharmacol Physiol] Abstract

Intensified Autophagy Compromises the Efficacy of Radiotherapy against Prostate Cancer
The authors investigated the autophagic activity in a series of patients with localized prostate tumors treated with radical radiotherapy, using the LC3A and the LAMP2a proteins as markers of autophagosome and lysosome cellular content, respectively. The role of autophagy on prostate cancer cell line resistance to radiation was also examined. [Biochem Biophys Res Commun] Abstract

Combined Effects of Nonylphenol and Bisphenol A on the Human Prostate Epithelial Cell Line RWPE-1
The authors analyzed the combined effects of nonylphenol and bisphenol A on the human prostate epithelial cell line RWPE-1 using two mathematical models based on the Loewe additivity theory and the Bliss independence theory. [Int J Environ Res Public Health] Full Article


Comparative Effectiveness of Mitoxantrone plus Prednisone versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer after Docetaxel Failure
Control arm data from two Phase III randomized control trials, SUN 1120 and TROPIC, were used to examine the efficacy of mitoxantrone plus prednisone versus prednisone alone among patients with postdocetaxel metastatic castrate-resistant prostate cancer. [Oncologist] Abstract

A Randomized Double-Blind Placebo Controlled Phase I-II Study on Clinical and Molecular Effects of Dietary Supplements in Men with Precancerous Prostatic Lesions. Chemoprevention or “Chemopromotion”?
Scientists present the results of a double-blind randomized controlled trial on the pharmacokinetic, clinical, and molecular activity of dietary supplements containing lycopene, selenium, and green tea catechins in men with multifocal high grade prostatic intraepithelial neoplasia and/or atypical small acinar proliferation. [Prostate] Abstract

Enter to Win a Travel Support Award to ISSCR2015!
Characterization of the Roles of Suppressor of Cytokine Signaling-3 in Prostate Cancer Development and Progression
The authors focus on the role of cytokine signaling-3 (SOCS-3) in prostate cancer development and prognosis, as well as the potential of SOCS-3 as a therapeutic target and diagnostic marker. [Asia Pac J Clin Oncol] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Trial Shows Benefit of ‘BRCA-Targeting’ Drug in Prostate Cancer
Men with prostate cancer benefit from treatment with the pioneering drug olaparib – the first cancer drug to target inherited mutations – according to the results of a major trial. [Press release from The Institute of Cancer Research discussing research presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting, Philadelphia] Press Release

A New Lease on Life for Prostate Tissue
What if a prostate cancer patient could learn which anti-cancer treatments would work best for him without having to swallow a single pill or endure a single intravenous line or injection? Research from Rutgers Cancer Institute of New Jersey involving the development of human organoid prostate models could have implications for how future therapy is guided for some of this population. [Press release from Rutgers Cancer Institute of New Jersey discussing research presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting, Philadelphia] Press Release

From our sponsor:
Modify hPSC genomes and enhance the physiological relevance of your research?
Watch the webinar now.
Prostate Cancer Foundation (PCF) Announces Inaugural Stupski Prize in Prostate Cancer Computational Oncology
The PCF announced the Stupski Prize in Prostate Cancer Computational Oncology, a first-in-field initiative designed to attract novel ideas to the rapidly changing field of large-scale cancer bioinformatics. [Prostate Cancer Foundation] Press Release

Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-Oncology Therapeutics
Astellas Pharma Inc. and Potenza Therapeutics, Inc. announced an exclusive research and development collaboration. The goal of the collaboration is to advance a portfolio consisting of programs with novel mechanisms of action targeting immune checkpoint pathways, co-stimulatory signals and regulatory T cells. [Astellas Pharma Inc.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Target Cancer Metabolism
May 26-28, 2015
Boston, United States

Visit our events page to see a complete list of events in the prostate cell community.
NEW Scientific Officer – Prostate Oncobiology (Cancer Research UK Manchester Institute)

Postdoctoral Position – Prostate Cell Biology & Cancer (Commissariat à l’Energie Atomique (CEA))

Postdoctoral Fellow – Genitourinary Cancers (Geisinger Health System)

Cancer Biologist (Wake Forest Baptist Medical Center)

Postdoctoral Positions – Stem Cells and Cancer (Brigham & Women’s Hospital)

Postdoctoral Position – Systems Genetics of Aggressive Prostate Cancer (National Institutes of Health)

Postdoctoral Research Fellow – Prostate Cancer and Breast Cancer (Baylor College of Medicine)

Postdoctoral Research Scientist – Prostate Cancer (Columbia University Medical Center)

Postdoctoral Fellow – Development, Progression and Chemotherapy Resistance of Cancers (University of Maryland School of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us